Skip to main content
Equibles
MREO logo

MREO · Mereo BioPharma Group plc

Track MREO — free

Use MREO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MREO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.28 +0.04 (+14.47%) At close · Sep 11
Rebalance outlook locked
Market Cap
$44.71M
Shares
159.69M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.28 Open$0.26 Day$0.26–0.29 52W close$0.24–2.31 Avg vol 30d7.0M Short int3.8M · 2.4% float · 3.4d Short vol50% Last earningsAug 11, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 11

Up next

Latest filing: 10-Q
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.5%
Year over year · more shares
Price change (1Y)
-86.3%
Trailing year
Short interest
2.4%
Latest settlement · 3.4 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −48%
below
Price vs 50-day avg −6%
below
RSI (14) 50
neutral
MACD trend Negative
52-week position 2%
near low
Momentum
relative strength
Very Weak
1-month return −9%
trailing
6-month return −18%
trailing
YTD return −33%
this year
Relative strength −36%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Distributing
-6% holders QoQ · +13 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.36% of float · ▼ -12.8% MoM · 3.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
60 holders — mid 3-yr range
Squeeze score 39
low risk · 0–100
Fundamentals
Fair
EPS growth +17%
Y/Y
Free cash flow $-31.0M
Quant / Vol
risk profile
Very High
Volatility 131%
annualized · 1-yr
Max drawdown −90%
past year
ATR 8.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−48% Bearish
Price vs 50-day avg
−6% Bearish
RSI (14)
50 Neutral
MACD trend
Negative Bearish
52-week position
2% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Distributing
-6% holders QoQ · +13 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.36% of float · ▼ -12.8% MoM · 3.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
60 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 2% Range high $2
vs 200-day avg -48% vs 50-day avg -6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MREO
Mereo BioPharma Group plc
this stock
$44.71M -32.9% — — 2.4%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
60
% held
35.9%
Net QoQ
-18.9M sh
Top holder
Rubric Capital Management…
Held Float
View
Held by Funds
Fund positions
6
View
Short & Settlement
Short Interest Falling
Shares short
3.8M
Days to cover
3.4d
Change
-551.3K sh
View
Short Volume
Short vol %
50%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
14
Value
$4
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
69.5%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$500.0K
Net income (FY)
$-41.9M
EPS diluted
$-0.05
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 19, 2026
This year
15
View
Proposed Sales
Value
$131.8K
Shares
28.3K
Filed
Sep 12, 2024
View
Exempt Offerings
Offering
$70.0M
Filed
Jun 12, 2020
View
Earnings & Events
Earnings Calls
Last call
Sep 7, 2026
View

Performance

5D 20D 120D MTD YTD
MREO +2.9% -9.1% -18.1% +4.9% -32.9%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY +4.1% -7.3% -36.0% +5.2% -44.9%
Key facts CIK 1719714 CUSIP 589492107 13F (30d) 33 filings 33 filers Visit website Investor relations